Development of New Drugs that Act Through Membrane Receptors and Involve an Action of Inverse Agonism

Publisher： Bentham Science Publishers

E-ISSN： 2212-3954|1|2|207-217

ISSN： 1574-8898

Source： Recent Patents on CNS Drug Discovery, Vol.1, Iss.2, 2006-06, pp. : 207-217

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

THCV, 5‐HT1A and schizophrenia

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 5, 2015-03 ,pp. : 1305-1318

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mechanisms of action of antiepileptic drugs

By Cook Aaron M   Bensalem-Owen Meriem K  

Therapy, Vol. 8, Iss. 3, 2011-05 ,pp. : 307-313

Future Medicine

Access to resources Recommend Favorite

Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis

By Martin T.   Sims N.   Ng K.  

Osteoporosis International, Vol. 19, Iss. 8, 2008-08 ,pp. : 1125-1138

Springer Publishing Company

Access to resources Recommend Favorite

Changes in Vascular Distensibility during Angiotensin-Converting Enzyme Inhibition Involve Bradykinin Type 2 Receptors

By  

Journal of Vascular Research, Vol. 41, Iss. 1, 2004-02 ,pp. : 18-27

Karger

Access to resources Recommend Favorite

Desloratadine Inhibits Constitutive and Histamine-Stimulated Nuclear Factor-κB Activity Consistent with Inverse Agonism at the Histamine H1 Receptor

By  

International Archives of Allergy and Immunology, Vol. 135, Iss. 4, 2004-12 ,pp. : 313-318

Karger

Access to resources Recommend Favorite